Reuters logo
in 4 months
BRIEF-Amicus Therapeutics completes enrollment in essence phase 3 epidermolysis bullosa clinical study
April 3, 2017 / 11:49 AM / in 4 months

BRIEF-Amicus Therapeutics completes enrollment in essence phase 3 epidermolysis bullosa clinical study

1 Min Read

April 3 (Reuters) - Amicus Therapeutics Inc

* Amicus Therapeutics completes enrollment in essence phase 3 epidermolysis bullosa clinical study

* Amicus Therapeutics Inc - top-line data from ongoing phase 3 clinical study (essence) of SD-101 are expected in Q3 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below